Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Leukemia

Volumn 24, Issue 10, 2010, Pages 1799-1804

  Makishima, H ^a   Jankowska, A M ^a   Tiu, R V ^a   Szpurka, H ^a   Sugimoto, Y ^a   Hu, Z ^a   Saunthararajah, Y ^a,c   Guinta, K ^a   Keddache, M A ^b   Putnam, P ^b   Sekeres, M A ^c   Moliterno, A R ^d   List, A F ^e   McDevitt, M A ^d,f   MacIejewski, J P ^a,c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; BONE MARROW CELL; FEMALE; GENE DELETION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY;

EID: 77957987676     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.167     Document Type: Letter

References (8)

1. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008; 112: 965-974.
2. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
3. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109-6116.
4. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
5. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 2009; 23: 610-614.
6. Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 2010; 24: 216-219.
7. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 2010; 115: 2731-2739.
8. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.